Primary prophylaxis of gastric varices is an important area of research, as gastric varices
are a common complication of cirrhosis of the liver. Cirrhosis is a condition in which the
liver becomes scarred and loses its ability to function properly, and it is a leading cause
of morbidity and mortality worldwide. Gastric varices occur in up to 30% of patients with
cirrhosis, and they can rupture, leading to life-threatening bleeding. The clinical,
epidemiological, and public health context of primary prophylaxis of gastric varices is
therefore the need to prevent the development of this complication in patients at risk for
cirrhosis and to reduce the associated morbidity and mortality. The clinical trials on
primary prophylaxis of gastric varices are therefore focused on evaluating the safety and
efficacy of various interventions, such as beta-blockers and endoscopic techniques, in
reducing the risk of gastric varices in patients with cirrhosis. The goal of this trial is to
find the most effective and safe strategies for primary prophylaxis of gastric varices, in
order to improve the outcomes for patients with cirrhosis.